Home »
Academic Articles »
C »
Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target
Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target
Xiaofeng Duan
(Department of Microbiology & Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States)
Stephen Iwanowycz
(Department of Microbiology & Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States)
Soo Ngoi
(Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States)
Megan Hill
(Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States)
Qiang Zhao
(Department of Pediatric Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Clinical Research Center for Cancer, Tianjin, China)
Bei Liu
(Department of Microbiology & Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States)
Bei Liu
(Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States)
Bei Liu
(The Pelotonia Institute for Immuno-Oncology at The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States)
Journal: Frontiers in Oncology
•
• Frontiers Media S.A.
• ISSN: 2234-943X
Abstract
During tumor development and progression, intrinsic and extrinsic factors trigger endoplasmic reticulum (ER) stress and the unfolded protein response, resulting in the increased expression of molecular chaperones to cope with the stress and maintain tumor cell survival. Heat shock protein (HSP) GRP94, also known as GP96, is an ER paralog of HSP90 and has been shown to promote survival signaling during tumor-induced stress and modulate the immune response through its multiple clients, including TLRs, integrins, LRP6, GARP, IGF, and HER2. Clinically, elevated expression of GRP94 correlates with an aggressive phenotype and poor clinical outcome in a variety of cancers. Thus, GRP94 is a potential molecular marker and therapeutic target in malignancies. In this review, we will undergo deep molecular profiling of GRP94 in tumor development and summarize the individual roles of GRP94 in common cancers, including breast cancer, colon cancer, lung cancer, liver cancer, multiple myeloma, and others. Finally, we will briefly review the therapeutic potential of selectively targeting GRP94 for the treatment of cancers.
Xiaofeng Duan, Stephen Iwanowycz, Soo Ngoi, et al. (2021). "Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target". Frontiers in Oncology. https://doi.org/10.3389/fonc.2021.629846